BI's Pradaxa antidote progresses

Share this article:

Boehringer Ingelheim has inched closer to a Pradaxa antidote. The company announced Wednesday that it is set to launch its first-ever test among patients. The blood drug antidote, called idarucizumab, has been tested in healthy patients, and this latest test will involve emergency rooms in 35 countries.

Lack of an antidote is a concern with oral anti-coagulants, which include BI's Pradaxa as well as the BMS/Pfizer treatment Eliquis and Janssen's Xarelto. There is one exception: standby warfarin which, as MedPage's editor-in-chief noted in an April piece, is reversible.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.